Lentiviral Vector (LV) CDMO Solutions

Lentiviral vectors (LVs) represent a cornerstone technology for next-generation therapeutic modalities, enabling durable genetic modifications crucial for sustained functional outcomes. As a premier contract development and manufacturing organization (CDMO), we provide integrated, scientifically rigorous CDMO solutions specifically engineered for LV production. Explore our broader capabilities in CDMO Solutions and Viral Vector CDMO Solutions.

LV Fundamentals

LVs, derived from modified lentiviruses (notably HIV-1), possess distinct advantages for genetic medicine. Their ability to transduce both dividing and quiescent cells, coupled with stable genomic integration and large transgene capacity (~8-10 kb), makes them indispensable tools. LVs are primarily leveraged in ex vivo cell engineering, forming the backbone of transformative autologous and allogeneic cell-based interventions. Key attributes include pseudotyping versatility and the potential for persistent transgene expression. The complexity of LV manufacturing, encompassing plasmid design, multi-plasmid transfection, vector production, purification, and stringent analytics, demands specialized CDMO expertise to overcome challenges like yield optimization, replication-competent lentivirus (RCL) prevention, and consistent potency.

Our LV CDMO Solutions

We deliver end-to-end LV development and manufacturing services designed for regulatory success and scalability. Investing in continuous improvement, we offer access to next-generation LV platforms. This includes third-generation SIN (self-inactivating) vector systems with enhanced safety profiles, optimized promoter/enhancer elements for controlled transgene expression, and strategies to minimize insertional mutagenesis risks. We also explore innovations in production efficiency (e.g., stable producer cell lines) and purification techniques.

LV Process & Analytical Development

Our scientific team designs robust, scalable upstream and downstream processes tailored to client-specific constructs. This includes:

Upstream Optimization: High-yield transient transfection platforms using optimized HEK 293-derived cell lines and media, focusing on titre enhancement and product quality consistency. We develop scalable bioreactor processes from bench to commercial scale.
Downstream Purification: Advanced chromatography (affinity, ion-exchange) and tangential flow filtration (TFF) strategies achieve high purity and recovery while effectively removing process impurities (host cell DNA/protein, residual plasmids) and critical safety contaminants (RCL).
Analytical Method Development & Qualification: A comprehensive analytical toolbox for identity, purity, potency, safety, and quantity assessment.

LV cGMP Manufacturing

Our state-of-the-art, flexible manufacturing suites support LV production under stringent cGMP compliance.

Commercial Readiness: Scalable processes designed for seamless transfer to large-scale manufacturing, ensuring continuity from clinical supply to market launch.
Fill/Finish: Aseptic filling into vials or cryobags under controlled environments, including cryopreservation and stability storage options.

Frequently Asked Questions

Q1: What is the critical quality attributes (CQAs) monitored during LV manufacturing, and how do you ensure consistency?

Essential CQAs include vector genome titre (VGT), infectious vector particle titre (IVP), vector purity (ratio of VGT to total particles, absence of process impurities), sterility, mycoplasma, endotoxin levels, and crucially, the absence of replication competent lentivirus (RCL). Consistency is ensured through rigorously developed and qualified manufacturing processes, stringent in-process controls (IPCs), and a comprehensive panel of validated release and stability-indicating analytical methods.

Q2: How do you mitigate the risk of RCL in your LV products?

RCL prevention is paramount. Our strategy employs a multi-layered approach:

Use of well-characterized, third-generation split-genome packaging systems minimizing sequence overlaps;
Rigorous testing of master/working cell banks and viral seeds;
Implementation of highly sensitive, validated in vitro RCL assays per regulatory guidelines during in-process testing and as a key lot release criterion.

Q3: What is your approach to developing potency assays for complex LV-based therapeutics?

Potency is a critical quality attribute demonstrating the biological function of the LV. We collaborate closely with clients to understand the therapeutic mechanism of action (MoA). Our approach involves developing custom, fit-for-purpose potency assays early in development. These can range from functional transduction assays using relevant target cell lines (measuring transgene expression/activity) to complex co-culture assays or animal models.

Our products and services are for research use only.